Chronic thromboembolic pulmonary hypertension

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:70591OMIM:612862I26.0
Who is this for?
Show terms as
2FDA treatments24Active trials91Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Chronic thromboembolic pulmonary hypertension, often called CTEPH (pronounced 'see-tef'), is a serious condition where old blood clots block the arteries that carry blood from the heart to the lungs. Unlike a fresh blood clot that can dissolve with medication, these clots become hard and scar-like over time, narrowing the blood vessels and making it very hard for the heart to pump blood through the lungs. This causes high blood pressure in the lung arteries — which is what 'pulmonary hypertension' means. Because the heart has to work much harder than normal, it gradually becomes strained and weakened. People with CTEPH often feel extremely tired, short of breath, and unable to do everyday activities they used to manage easily. Some people develop CTEPH after a known pulmonary embolism (a blood clot in the lungs), but in others, the clots were never noticed before diagnosis. The good news is that CTEPH is one of the few forms of pulmonary hypertension that can potentially be cured. A surgery called pulmonary endarterectomy (PEA) removes the scar tissue from the lung arteries and can dramatically improve or even normalize blood pressure in the lungs. For people who cannot have surgery, a procedure called balloon pulmonary angioplasty (BPA) and medications such as riociguat (Adempas) are available. With the right treatment, many people with CTEPH can live longer, more active lives.

Also known as:

Key symptoms:

Shortness of breath, especially during physical activityExtreme tiredness or fatigue that does not improve with restFeeling dizzy or lightheaded, especially when activeFainting or near-fainting spellsChest pain or pressureSwelling in the legs, ankles, or feetBluish tint to the lips or fingertips (called cyanosis)Rapid or irregular heartbeatCoughing, sometimes with bloodReduced ability to exercise or do physical tasks

Clinical phenotype terms (37)— hover any for plain English
Increased pulmonary vascular resistanceHP:0005317Pulmonary embolismHP:0002204Deep venous thrombosisHP:0002625Reduced vital capacityHP:0002792Reduced FEV1/FVC ratioHP:0030877Cardiac shuntHP:0001693Abnormality of blood and blood-forming tissuesHP:0001871Antiphospholipid antibody positivityHP:0003613Recurrent thromboembolismHP:0004831
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Jul 2026What is the Role of the Exposome in Pulmonary Hypertension

Poitiers University Hospital

TrialNOT YET RECRUITING
Nov 2025Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension

Damascus University

TrialRECRUITING
Sep 2025Impact of BPA in CTEPH on Cardiac and Pulmonary Physiology Assessed by CMR-derived 4D Flow Haemodynamics

Kerckhoff Klinik

TrialRECRUITING
Aug 2025Rutgers University Study of the Genetics of Pulmonary Hypertension

Rutgers, The State University of New Jersey

TrialRECRUITING
May 2025Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients

Beijing Chao Yang Hospital — NA

TrialNOT YET RECRUITING
May 2025Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension

Irina E. Chazova

TrialRECRUITING
Mar 2025Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

Suqiao Yang — PHASE3

TrialRECRUITING
Jan 2025Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

Dr Sudarshan Rajagopal — PHASE3

TrialRECRUITING
Jan 2025Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism

Ester Ashraf Faried Beshay

TrialRECRUITING
Jul 2024Switching of Sildenafil to Riociguat in CTEPH Patients

Chinese University of Hong Kong — PHASE4

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

XARELTO

RIVAROXABAN· Janssen Pharmaceuticals, Inc.■ Boxed Warning

for reduction in the risk of recurrence of DVT or PE

Adempas

riociguat· Bayer■ Boxed WarningOrphan Drug
Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO fun

Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class

Clinical Trials

20 recruitingView all trials with filters →
Phase 32 trials
Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)
Phase 3
Actively Recruiting
· Sites: Beijing, China; Beijing, China +1 more · Age: 1899 yrs
Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
Phase 3
Actively Recruiting
PI: Sudarshan Rajagopal, MD, PhD (Duke Health System) · Sites: Durham, North Carolina · Age: 1899 yrs
Phase 41 trial
Switching of Sildenafil to Riociguat in CTEPH Patients
Phase 4
Actively Recruiting
· Sites: Hong Kong · Age: 1899 yrs
Other17 trials
Rutgers University Study of the Genetics of Pulmonary Hypertension
Actively Recruiting
PI: Tara Matise, Ph.D. (Rutgers, The State University of New Jersey) · Sites: Piscataway, New Jersey · Age: 1899 yrs
Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism
Actively Recruiting
PI: Ester A Faried, Resident (Assiut University) · Sites: Asyut · Age: 1880 yrs
Cardiac Self-Efficacy in Patients With Chronic Thromboembolic Pulmonary Hypertension
Actively Recruiting
PI: Mohammad B Izzat, FRCS(CTh) (Damascus University School of Medicine) · Sites: Damascus, Rif-dimashq Governorate
Impact of BPA in CTEPH on Cardiac and Pulmonary Physiology Assessed by CMR-derived 4D Flow Haemodynamics
Actively Recruiting
· Sites: Bad Nauheim, Hesse · Age: 1899 yrs
Pulmonary Hypertension Association Registry
Actively Recruiting
· Sites: Phoenix, Arizona; Sacramento, California +50 more
Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
Actively Recruiting
PI: Laurent BERTOLETTI, PhD (Centre Hospitalier Universitaire de Saint Etienne) · Sites: Saint-Etienne · Age: 1899 yrs
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
Actively Recruiting
PI: Grzegorz Kopeć, MD, Phd (Krakowski Szpital Specjalistyczny im. Jana Pawła I) · Sites: Krakow
Biological Sex and CTEPH-related RV Dysfunction and Recovery (BIOSPHeRe)
Actively Recruiting
· Sites: Murray, Utah · Age: 1899 yrs
Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
Enrolling by Invitation
PI: Henning Gall, MD, PhD (University Clinic Giessen and Marburg - Campus Gie) · Sites: Giessen, Hesse · Age: 1899 yrs
Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Database in China
Actively Recruiting
· Sites: Beijing · Age: 1499 yrs
Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension
Actively Recruiting
· Sites: Moscow · Age: 1899 yrs
Chinese PE Multimodality Imaging Artificial Intelligence Study
Actively Recruiting
PI: Zhenguo Zhai, PhD (China-Japan Friendship Hospital) · Sites: Beijing · Age: 1499 yrs
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Actively Recruiting
· Sites: Beijing; Beijing · Age: 1899 yrs
Chronic Thromboembolic Disease Registry
Actively Recruiting
PI: Miles Conrad, MD (University of California, San Francisco) · Sites: San Francisco, California · Age: 1899 yrs
TrEatment Approach in the Multimodal Era Registry
Active
PI: Nick H Kim, MD (University of California, San Diego) · Sites: San Diego, California; Evanston, Illinois +23 more · Age: 1899 yrs
Frailty, Physical Capacity and Lung Function in Postoperative Pulmonary Endarterectomy Patients
Actively Recruiting
PI: Rafael M Ianotti, PT (Instituto do Coração - Hospital das Clínicas da Fa) · Sites: São Paulo, São Paulo · Age: 1899 yrs
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
Actively Recruiting
PI: Zhihong Liu, MD,PhD (Fuwai Hospital, National Center for Cardiovascular) · Sites: Beijing · Age: 5100 yrs

Specialists

Showing 25 of 91View all specialists →
SM
Silvia Ulrich, MD
Specialist
PI on 2 active trials
JM
Joseph Mammarappallil, MD
DURHAM, NC
Specialist
PI on 2 active trials
SM
Silvia Ulrich Somaini, MD
Specialist
PI on 2 active trials
OP
Olaf Mercier, MD, PhD
Specialist
PI on 1 active trial
ZM
Zhihong Liu, MD,PhD
Specialist
PI on 1 active trial
GP
Gerald SIMONNEAU, MD, PhD
Specialist
PI on 1 active trial
DP
Dominique MUSSET, MD, PhD
Specialist
PI on 1 active trial
AM
Andy Swift, MD
YUMA, AZ
Specialist
PI on 1 active trial1 Chronic thromboembolic pulmonary hypertension publication
WP
Wild Jim, PhD
Specialist
PI on 1 active trial
MM
Mathieu LIBERATORE, MD
Specialist
PI on 1 active trial
SM
Syed Quadery, MBBS
Specialist
PI on 1 active trial
IM
Irene Lang, MD
FALL RIVER, MA
Specialist
PI on 3 active trials1 Chronic thromboembolic pulmonary hypertension publication
KM
Kim M Kerr, MD
Specialist
PI on 2 active trials
SP
Sudarshan Rajagopal, MD, PhD
DURHAM, NC
Specialist
PI on 3 active trials
RP
Rafael M Ianotti, PT
Specialist
PI on 2 active trials
ER
Ester A Faried, Resident
Specialist
PI on 1 active trial
UM
Ulrika Birgersdotter-Green, MD
SAN DIEGO, CA
Specialist
PI on 1 active trial
SD
Silvia Ulrich Somaini, Prof. Dr.
Specialist
PI on 2 active trials
FP
F.A. Klok, MD PhD
Specialist
PI on 2 active trials
RM
Raffaele Pesavento, MD
Specialist
PI on 1 active trial
AM
Ayesha Zia, M.D.
DALLAS, TX
Specialist
PI on 1 active trial
RP
Roopen Arya, MBChB, PhD
Specialist
PI on 1 active trial
LD
Lu Hua, Dr.
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Chronic thromboembolic pulmonary hypertension.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Chronic thromboembolic pulmonary hypertensionForum →

No community posts yet. Be the first to share your experience with Chronic thromboembolic pulmonary hypertension.

Start the conversation →

Latest news about Chronic thromboembolic pulmonary hypertension

5 articles
ResearchRSSApr 24, 2026
Study shows PH treatment needs drop as kids with BPD grow
A new study found that babies born early who develop a lung condition called bronchopulmonary dysplasia (BPD) often need medications to treat high blood pressur
AdvocacyRSSApr 22, 2026
Pushing through can do more harm than good when living with PH
People with pulmonary hypertension (PH) often feel pressure to push through exhaustion and symptoms like chest pain, but this approach can actually make their c
AdvocacyRSSApr 22, 2026
Artemis II reminds me to dream big for a pulmonary hypertension cure
This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a se
NewsRSSApr 22, 2026
Growing up with PH meant answering a lot of questions from peers
A person with pulmonary hypertension (PH), a rare lung disease that makes it hard for the heart to pump blood through the lungs, shares what it was like growing
NewsRSSApr 22, 2026
I’m learning how to live fully, not just survive, with pulmonary hypertension
A person with pulmonary hypertension shares how their life has changed as their health improved. When they were first diagnosed, just surviving day-to-day was t
See all news about Chronic thromboembolic pulmonary hypertension

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Am I a candidate for pulmonary endarterectomy surgery, and what would make me eligible or ineligible?,If I cannot have surgery, is balloon pulmonary angioplasty an option for me?,Which blood thinner is best for me, and how will we monitor it?,Should I be tested for inherited blood clotting disorders?,What symptoms should prompt me to go to the emergency room immediately?,How often do I need follow-up appointments and what tests will be repeated?,Are there any clinical trials I should consider?

Common questions about Chronic thromboembolic pulmonary hypertension

What is Chronic thromboembolic pulmonary hypertension?

Chronic thromboembolic pulmonary hypertension, often called CTEPH (pronounced 'see-tef'), is a serious condition where old blood clots block the arteries that carry blood from the heart to the lungs. Unlike a fresh blood clot that can dissolve with medication, these clots become hard and scar-like over time, narrowing the blood vessels and making it very hard for the heart to pump blood through the lungs. This causes high blood pressure in the lung arteries — which is what 'pulmonary hypertension' means. Because the heart has to work much harder than normal, it gradually becomes strained and

How is Chronic thromboembolic pulmonary hypertension inherited?

Chronic thromboembolic pulmonary hypertension follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Chronic thromboembolic pulmonary hypertension typically begin?

Typical onset of Chronic thromboembolic pulmonary hypertension is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Chronic thromboembolic pulmonary hypertension?

Yes — 20 recruiting clinical trials are currently listed for Chronic thromboembolic pulmonary hypertension on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Chronic thromboembolic pulmonary hypertension?

25 specialists and care centers treating Chronic thromboembolic pulmonary hypertension are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.